ADC THERAPEUTICS SA's ticker is ADCT and the CUSIP is H0036K147. A total of 57 filers reported holding ADC THERAPEUTICS SA in Q2 2023. The put-call ratio across all filers is 37.00 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $192,481 | -12.6% | 89,526 | -20.7% | 0.00% | – |
| Q1 2023 | $220,167 | -27.1% | 112,906 | +43.5% | 0.00% | – |
| Q4 2022 | $302,000 | -18.8% | 78,670 | +2.0% | 0.00% | – |
| Q3 2022 | $372,000 | -41.5% | 77,103 | -3.6% | 0.00% | – |
| Q2 2022 | $636,000 | -42.3% | 79,976 | +6.6% | 0.00% | – |
| Q1 2022 | $1,102,000 | -17.8% | 75,030 | +13.1% | 0.00% | – |
| Q4 2021 | $1,340,000 | -28.3% | 66,352 | -3.6% | 0.00% | -100.0% |
| Q3 2021 | $1,869,000 | +14.3% | 68,815 | +2.7% | 0.00% | 0.0% |
| Q2 2021 | $1,635,000 | +9.0% | 67,034 | +9.1% | 0.00% | – |
| Q1 2021 | $1,500,000 | -36.8% | 61,419 | -17.1% | 0.00% | -100.0% |
| Q4 2020 | $2,372,000 | +28.6% | 74,102 | +32.5% | 0.00% | 0.0% |
| Q3 2020 | $1,845,000 | -39.1% | 55,925 | -13.6% | 0.00% | 0.0% |
| Q2 2020 | $3,029,000 | – | 64,710 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vantage Consulting Group Inc | 1,186,215 | $9,430,000 | 5.29% |
| GCM Grosvenor Holdings, LLC | 1,298,012 | $10,319,000 | 2.33% |
| Redmile Group, LLC | 7,512,029 | $59,721,000 | 2.28% |
| MPM BioImpact LLC | 334,384 | $2,658,000 | 0.74% |
| Indie Asset Partners, LLC | 93,989 | $747,000 | 0.66% |
| Eventide Asset Management | 1,879,959 | $14,946,000 | 0.32% |
| Walleye Capital LLC | 888,700 | $7,065,000 | 0.20% |
| Endurant Capital Management LP | 58,967 | $469,000 | 0.16% |
| HHLR ADVISORS, LTD. | 500,000 | $3,975,000 | 0.08% |
| Matrix Capital Management Company, LP | 400,000 | $3,180,000 | 0.07% |